HSV-based vectors optimised for antigen delivery to dendritic cells by the deletion of HSV genes

First clinical vaccination data has been obtained using an HSV vector expressing full length tyrosinase, gp100 and MART-1 to transduce DC from melanoma patients.

Biovex has developed HSV-based vectors optimised for antigen delivery to dendritic cells by the deletion of HSV genes which usually inhibit DC function. These deliver antigens to DC at very high efficiency and activate the transduced cells similarly to LPS. Based on this technology, Biovex began a clinical program where an HSV vector expressing full length tyrosinase, gp100 and MART-1 was used to transduce DC from melanoma patients which were then to be used for vaccination. Due to a change in emphasis, Biovex is no longer progressing this program but has, as a result, considerable internal expertise, reagents and methodology which could be of use to the project if partners would like to use HSV-based technology for the delivery of antigens to DC. This includes the vectors themselves, and the shuttle plasmids into which antigens are inserted and provides the possibility of using these vectors for a variety of pre-clinical, and ultimately clinical studies.

• stimulus type
• lipopolysaccharide

• molecule type
• gp100 antigen,
• tyrosinase,
• Melan A

• cell type
• dendritic cell

• organism type
• simplex virus,
• Homo sapiens

• experimental design type
• in vivo design experiment

• experimental factor type
• Clinical treatment factor

created over 15 years ago (2 March 2009)    last modified over 13 years ago (14 October 2011)   [ RDF ]   [ RelFinder ]